Age-Related Macular Degeneration Clinical Trial
Official title:
Assessment of Macular Edema Using HRT Technique
Age Related Macular Degeneration (ARMD) is the most common cause of irreversible blindness
in people of age 50 or older in the western populations. ARMD has two forms, the wet and the
dry forms. The wet form is more serious and can lead to irreversible loss of vision. In the
wet form of ARMD, new blood vessels grow under the retina. These blood vessels leak blood
and fluid and cause the retina and the macula to swell. So the thickness of the macula
increases.
One of the key factors in the treatment of wet ARMD is early diagnosis and treatment to
prevent complete visual loss. In this research, we are going to use a technique, called the
Heidelberg retinal tomograph (HRT) to measure and compare the thickness of the macula in
healthy controls and in patients suspected of having ARMD. HRT is a non-invasive imaging
system that uses laser to measure the thickness of the macula. This allows us to come up
with a quite simple and easy-to-use technique that helps us to diagnose wet ARMD early and
treat it before visual acuity is completely lost.
Introduction: Age-related macular degeneration (ARMD) is a spectrum of related diseases that
affects the macula and it has been traditionally classified into early and late stages with
its dry (non-exudative) and wet (exudative) forms. Although the advanced form of AMD is less
common, the potential visual loss is more significant. The Beaver Dam Eye Study reported
that 30% of individuals aged 75 and older have some form of AMD, whereas 7% of those aged 75
and older have an advanced form. Recent studies estimate that 8 million Americans are
considered to be at risk for developing advanced ARMD in the next 5 years, whereas 1.75
million are currently affected with the advanced form of the disease.
Wet AMD is characterized by proliferation of abnormal vessels in the choroid. These
choroidal neovascular membranes may proliferate into the subretinal space and retina and
leak fluid and blood. This fluid may accumulate in the macula area causing macular edema
(ME), the final common pathway for visual loss in many diseases. There are currently no
treatments that can reverse or repair the destruction and restore visual acuity. The
critical time for any intervention is early in the disease, when visual acuity has been
minimally affected. Due to the irreversible nature of the disease and a realistic risk of
permanent vision loss, there is an increased need to improve the accuracy of identifying the
presence and extent of MEvwith a prompt referral to a retina specialist following diagnosis.
ME has traditionally been assessed clinically using a combination of slit lamp biomicroscopy
and fluorescein angiography. New imaging techniques such as optical coherence tomography
(OCT), the retinal thickness analyser (RTA), and the Heidelberg retinal tomograph (HRT)
confocal scanning laser ophthalmoscope facilitate qualitative assessments of the degree of
ME. Although OCT has a high sensitivity and specificity for the detection of ME within 500
microns of the fovea, this resolution decreases outside this area. RTA has shown lower
sensitivity (57%) for the detection of ME. 4 The Heidelberg Retinal Tomograph II (HRT II,
Heidelberg Engineering) is a non-invasive, confocal scanning laser imaging system that uses
a red (670 nm) diode laser to perform a series of optical sections of the macula area
covering a 15°x15° field of view, corresponding to approximately 4.5 x 4.5 mm on the retina.
The reflected laser light intensity is processed assisting with a quantitative diagnosis of
ME. If ME is present, the amount of scatter inside the swollen retina increases, reducing
retinal reflectance.
A few studies have evaluated the HRT for detecting ME. Tong and co-workers have proposed a
scoring system for macular image assessment using HRT in patients with diabetic maculopathy.
Guan and co-workers found the HRT to have a sensitivity and specificity of 92% and 68% for
detecting ME in the diabetic population when using clinical assessment as the gold standard.
To the best of our knowledge, no studies have yet validate the used HRT for the detection of
ME as an early sign of exudative disease in ARMD patients.
Purpose: The purpose of the study is to assessed the sensitivity, specificity, and
repeatability, of HRT for the presence of ME in exudative ARMD Design: Prospective,
observational study. Objectives: 1) Assessment of healthy volunteers to obtain baseline
normal measurements of macular thickening. 2) Measurements in ARMD patient's referred to a
retinal specialist clinic with the diagnosis of exudative form of ARMD Patients, Material,
and Methods: 1) normal controls (N=20): baseline measurements centered at the fovea will be
taken. Three consecutive measurements will be performed (within-session repeatability). 2)
Patients: New patients referred by general ophthalmologists to the retina specialist for
possible diagnosis of ARMD, exudative formed, will be included in the study. All patients
will undergo a full ophthalmologic exam by the same retinal specialist who will determine
the clinical presence of ME (gold standard) using fundus contact lens examination. In some
cases, fluorescein angiograms will be use as an ancillary test. All patients will then be
evaluated using HRT for the presence of ME using the macula edema module. The technician
performing the test will be mask to the patients' clinical diagnosis. Three consecutive
measurements will be performed in 4 quadrants (500-1000-1500 microns/ 4 quadrants) (color
map and reflectivity) 3) Comparison will be made between the clinical diagnosis of ME (gold
standard) and results obtained by the HRT. Features compared: 1) presence/absence of ME 2)
spacial agreement between areas of elevated retina encountered by HRT Vs clinical
examination.
;
Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05984927 -
NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05536297 -
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
|
Phase 3 | |
Recruiting |
NCT04101604 -
Biomarkers of Common Eye Diseases
|
||
Completed |
NCT04005352 -
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
|
Phase 3 | |
Withdrawn |
NCT02873351 -
A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration
|
Phase 2 | |
Active, not recruiting |
NCT02802657 -
Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration
|
Phase 4 | |
Not yet recruiting |
NCT02864472 -
Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose
|
Phase 4 | |
Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT02035722 -
Intravitreal Injections-related Anxiety
|
Phase 2/Phase 3 | |
Completed |
NCT01445548 -
Sirolimus for Advanced Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT01175395 -
20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
Recruiting |
NCT01048476 -
Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01174407 -
Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration
|
N/A | |
Terminated |
NCT00712491 -
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT00345176 -
Age-Related Eye Disease Study 2 (AREDS2)
|
Phase 3 | |
Completed |
NCT02140151 -
Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT02555306 -
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Recruiting |
NCT04796545 -
Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration
|
N/A | |
Completed |
NCT03166202 -
Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator
|
||
Completed |
NCT01397409 -
Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)
|
Phase 2 |